Loss-of-Function Variants Associated with Gastric Cancer Risk
the Cancer Therapy Advisor take:
Loss-of-function mutations in ATM were associated with an increased risk for developing gastric cancer, according to an article published online in the journal Nature Genetics.
A Genome-wide association study (GWAS) in a European population with information on 2,500 cases of gastric cancer and 205,652 controls was reported.
The authors found a new association between gastric cancer and the loss-of-function mutations in ATM gene test, P = 8.0 × 10−12; OR = 4.74). Patients carrying the loss-of-function mutations were diagnosed with cancer significantly earlier in age than those not carrying the variations.
Furthermore, a combination of the loss-of-function mutations p.Gln852, p.Ser644, and p.Tyr103 (combined minor allele frequency (MAF) = 0.3%) were linked with pancreatic (OR = 3.81) and prostate (OR = 2.18) cancer and indicated a risk of breast (OR = 1.82) and colorectal (OR = 1.97) cancer.
Results confirmed a relationship between the three loci associated with gastric cancer in Asia (MUC1, PRKAA1 and PSCA) and gastric cancer in Europeans.
Loss-of-function mutations in ATM were associated with an increased risk for developing gastric cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma